Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposomes + Sindilizumab in second-line and later advanced gastric cancer
ChiCTR2600118190Phase 2Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome and sindilizumab in gastric adenocarcinoma, sponsored by Hubei Cancer Hospital. Primary endpoint: Progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
irinotecan liposomesindilizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600118190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118190.